Literature DB >> 28291428

The durability of endoscopic third ventriculostomy and ventriculoperitoneal shunts in children with hydrocephalus following posterior fossa tumor resection: a systematic review and time-to-failure analysis.

Michael C Dewan1, Jaims Lim1, Chevis N Shannon1, John C Wellons1.   

Abstract

OBJECTIVE Up to one-third of patients with a posterior fossa brain tumor (PFBT) will experience persistent hydrocephalus mandating permanent CSF diversion. The optimal hydrocephalus treatment modality is unknown; the authors sought to compare the durability between endoscopic third ventriculostomy (ETV) and ventriculoperitoneal shunt (VPS) therapy in the pediatric population. METHODS The authors conducted a systematic review of articles indexed in PubMed between 1986 and 2016 describing ETV and/or VPS treatment success/failure and time-to-failure rate in patients < 19 years of age with hydrocephalus related to a PFBT. Additionally, the authors conducted a retrospective review of their institutional series of PFBT patients requiring CSF diversion. Patient data from the systematic review and from the institutional series were aggregated and a time-to-failure analysis was performed comparing ETV and VPS using the Kaplan-Meier method. RESULTS A total of 408 patients were included from 12 studies and the authors' institutional series: 284 who underwent ETV and 124 who underwent VPS placement. The analysis included uncontrolled studies with variable method and timing of CSF diversion and were subject to surgeon bias. No significant differences between cohorts were observed with regard to age, sex, tumor grade or histology, metastatic status, or extent of resection. The cumulative failure rate of ETV was 21%, whereas that of VPS surgery was 29% (p = 0.105). The median time to failure was earlier for ETV than for VPS surgery (0.82 [IQR 0.2-1.8] vs 4.7 months [IQR 0.3-5.7], p = 0.03). Initially the ETV survival curve dropped sharply and then stabilized around 2 months. The VPS curve fell gradually but eventually crossed below the ETV curve at 5.7 months. Overall, a significant survival advantage was not demonstrated for one procedure over the other (p = 0.21, log-rank). However, postoperative complications were higher following VPS (31%) than ETV (17%) (p = 0.012). CONCLUSIONS ETV failure occurred sooner than VPS failure, but long-term treatment durability may be higher for ETV. Complications occurred more commonly with VPS than with ETV. Limited clinical conclusions are drawn using this methodology; the optimal treatment for PFBT-related hydrocephalus warrants investigation through prospective studies.

Entities:  

Keywords:  EOR = extent of resection; ETV = endoscopic third ventriculostomy; PFBT = posterior fossa brain tumor; VPS = ventriculoperitoneal shunt; durability; endoscopic third ventriculostomy; hydrocephalus; pediatric; posterior fossa; tumor; ventriculoperitoneal shunt

Mesh:

Year:  2017        PMID: 28291428     DOI: 10.3171/2017.1.PEDS16536

Source DB:  PubMed          Journal:  J Neurosurg Pediatr        ISSN: 1933-0707            Impact factor:   2.375


  12 in total

1.  The role of external ventricular drainage for the management of posterior cranial fossa tumours: a systematic review.

Authors:  Pasquale Anania; Denise Battaglini; Alberto Balestrino; Alessandro D'Andrea; Alessandro Prior; Marco Ceraudo; Diego Criminelli Rossi; Gianluigi Zona; Pietro Fiaschi
Journal:  Neurosurg Rev       Date:  2020-06-03       Impact factor: 3.042

2.  Predictive factors associated with ventriculoperitoneal shunting after posterior fossa tumor surgery in children.

Authors:  Leonie Johanna Helmbold; Gertrud Kammler; Jan Regelsberger; Friederike Sophie Fritzsche; Pedram Emami; Ulrich Schüller; Kara Krajewski
Journal:  Childs Nerv Syst       Date:  2019-03-30       Impact factor: 1.475

3.  Endoscopic third ventriculostomy prior to resection of posterior fossa tumors in children.

Authors:  Fabio Frisoli; Michael Kakareka; Kristina A Cole; Angela J Waanders; Phillip B Storm; Shih-Shan Lang
Journal:  Childs Nerv Syst       Date:  2019-03-20       Impact factor: 1.475

4.  Postoperative intraventricular blood: a new modifiable risk factor for early postoperative symptomatic hydrocephalus in children with posterior fossa tumors.

Authors:  Ananth P Abraham; Ranjith K Moorthy; Lakshmanan Jeyaseelan; Vedantam Rajshekhar
Journal:  Childs Nerv Syst       Date:  2019-05-18       Impact factor: 1.475

5.  Endoscopic third ventriculostomy versus ventriculoperitoneal shunt in pediatric and adult population: a systematic review and meta-analysis.

Authors:  Apurva Pande; Nayan Lamba; Marco Mammi; Paulos Gebrehiwet; Alyssa Trenary; Joanne Doucette; Stefania Papatheodorou; Adomas Bunevicius; Timothy R Smith; Rania A Mekary
Journal:  Neurosurg Rev       Date:  2020-05-31       Impact factor: 3.042

6.  The effect of tumor removal via craniotomies on preoperative hydrocephalus in adult patients with intracranial tumors.

Authors:  Sayied Abdol Mohieb Hosainey; Benjamin Lassen; John K Hald; Eirik Helseth; Torstein R Meling
Journal:  Neurosurg Rev       Date:  2018-08-17       Impact factor: 3.042

7.  Tumor-related hydrocephalus in infants: a narrative review.

Authors:  Aaron M Yengo-Kahn; Michael C Dewan
Journal:  Childs Nerv Syst       Date:  2021-03-26       Impact factor: 1.475

8.  FSI simulation of CSF hydrodynamic changes in a large population of non-communicating hydrocephalus patients during treatment process with regard to their clinical symptoms.

Authors:  Seifollah Gholampour
Journal:  PLoS One       Date:  2018-04-30       Impact factor: 3.240

Review 9.  Comparing the Efficiency of Two Treatment Methods of Hydrocephalus: Shunt Implantation and Endoscopic Third Ventriculostomy.

Authors:  Seifollah Gholampour; Mehrnoush Bahmani; Azadeh Shariati
Journal:  Basic Clin Neurosci       Date:  2019-05-01

10.  Treating empyema thoracis using video-assisted thoracoscopic surgery and open decortication procedures: a systematic review and meta-analysis by meta-mums tool.

Authors:  Massoud Sokouti; Ramin Sadeghi; Saeid Pashazadeh; Saeed Eslami Hasan Abadi; Mohsen Sokouti; Morteza Ghojazadeh; Babak Sokouti
Journal:  Arch Med Sci       Date:  2018-08-23       Impact factor: 3.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.